MARK T GLADWIN
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD434600
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15213
Personal information
See more information about MARK T GLADWIN at radaris.comName
Address
Phone
636 Woodvalley Dr, Pittsburgh, PA 15238
Pittsburgh, PA
636 Woodvalley Dr, Pittsburgh, PA 15238
Professional information
Dr. Mark T Gladwin, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
10 Ctr Dr SUITE 10, Bethesda 20892
(301) 435-2310 (Phone), (301) 451-7091 (Fax)
FALK CLINIC
3601 5Th Ave SUITE 4, Pittsburgh 15213
(412) 648-3200 (Phone), (412) 647-5480 (Fax)
(301) 435-2310 (Phone), (301) 451-7091 (Fax)
FALK CLINIC
3601 5Th Ave SUITE 4, Pittsburgh 15213
(412) 648-3200 (Phone), (412) 647-5480 (Fax)
Certifications:
Critical Care Medicine, 1999, Internal Medicine, 1994, Pulmonary Disease, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Miami / School of Medicine
Graduated: 1991
Oregon Health Sciences University
National Institutes Of Health Clinical Center
University Of Washington Medical Center
Warren G. Magnuson Clinical Center
University of Miami / School of Medicine
Graduated: 1991
Oregon Health Sciences University
National Institutes Of Health Clinical Center
University Of Washington Medical Center
Warren G. Magnuson Clinical Center
Five-Coordinate Neuroglobin And Use Thereof As A Blood Substitute
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 16, 2010
Appl. No.:
12/817085
Inventors:
Mark T. Gladwin - Pittsburgh PA, US
Daniel B. Kim-Shapiro - Winston-Salem NC, US
Mauro Tiso - Bethesda MD, US
Daniel B. Kim-Shapiro - Winston-Salem NC, US
Mauro Tiso - Bethesda MD, US
International Classification:
A61K 38/41, A61K 35/14, A61K 35/16, A61K 35/18, A61P 7/06, A61P 7/08, A61P 7/00, A61P 9/10, A61P 17/02, A61P 9/12
US Classification:
424530, 424529, 424531, 424533, 514 134, 514 151
Abstract:
Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.
Use Of Nitrite Salts For The Treatment Of Cardiovascular Conditions
US Patent:
2010024, Sep 30, 2010
Filed:
Mar 26, 2010
Appl. No.:
12/748184
Inventors:
Mark T. Gladwin - Pittsburgh PA, US
Alan N. Schechter - Bethesda MD, US
David J. Lefer - Atlanta GA, US
Rakesh P. Patel - Hoover AL, US
Christian J. Hunter - Boston MA, US
Gordon G. Power - Redlands CA, US
Daniel B. Kim-Shapiro - Winston-Salem NC, US
Ryszard Marek Pluta - Bethesda MD, US
Edward H. Oldfield - Philomont VA, US
Alan N. Schechter - Bethesda MD, US
David J. Lefer - Atlanta GA, US
Rakesh P. Patel - Hoover AL, US
Christian J. Hunter - Boston MA, US
Gordon G. Power - Redlands CA, US
Daniel B. Kim-Shapiro - Winston-Salem NC, US
Ryszard Marek Pluta - Bethesda MD, US
Edward H. Oldfield - Philomont VA, US
International Classification:
A61K 33/00, A61K 31/198, A61P 9/00, A61P 11/00
US Classification:
424718, 514565
Abstract:
It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.